trending Market Intelligence /marketintelligence/en/news-insights/trending/8Mu4NqKTCOeedkvgQJ41dQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UCB drug improves blood disorder symptoms in mid-stage study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

UCB drug improves blood disorder symptoms in mid-stage study

Brussels-based UCB SA said its experimental drug rozanolixizumab helped patients with primary immune thrombocytopeni achieve clinically relevant improvements in platelet count and reduced immunoglobin G levels in a mid-stage trial called TP0001.

Primary immune thrombocytopeni is an autoimmune bleeding disorder in which the blood does not clot due to a low number of platelets. Symptoms mainly include spontaneous bruising, bleeding and fatigue.

Rozanolixizumab, which was found to be safe and well-tolerated in patients, was administered in multiple doses, and subjects were monitored for an eight-week observation period after completing treatment. The company found improvements in platelet count across all dose groups and decreases in immunoglobin G, which is responsible for the removal and destruction of new or existing platelets in the body.

UCB presented the data at the 2019 American Society of Hematology meeting. The company's medicine was granted the orphan designation by the U.S. Food and Drug Administration in 2018 and the European Commission earlier this year.